Fig. 1

Molecular breast images in the mediolateral oblique projection from a 73-year-old patient with biopsy-proven invasive lobular carcinoma (Table 1, tumor #21). At blinded review, MBI performed with 300 MBq ^99mTc sestamibi (a) was interpreted as negative; MBI performed 3 days later with 300 MBq ^99mTc maraciclatide (b) was interpreted as assessment category 4. The lesion extent was 9.3 cm (arrows). Final pathology revealed grade I invasive lobular carcinoma of luminal A subtype, forming a 2.5-cm mass